中国·上海
2022年12月13日
安腾瑞霖（上海）生物科技有限公司（以下简称“安腾瑞霖”）与上海康抗生物技术有限公司（以下简称“康抗生物”）宣布达成战略合作，双方将本着平等互利、优势互补的原则，结成长期、全面的战略伙伴关系，实现资源共享和共同发展。在合作期间，安腾瑞霖将作为CDMO合作伙伴全程为康抗生物的创新药物提供细胞株构建、细胞库建库及检定、工艺开发及优化、分析方法开发及确认、工艺转移和确认、毒理研究样品研制、临床样品生产、商业化规模生产、稳定性研究、IND & NDA申报相关文件撰写等在内的服务。
■■■■
康抗生物创始人、CEO姜伟东博士表示：“康抗生物是一家专注于提供创新药物的生物技术公司，以满足于临床未能满足的医疗需求。公司致力于开发免疫激动剂和多特异性抗体的创新型前药分子，以降低药物毒性、提高药物疗效。很高兴能与安腾瑞霖达成本次战略合作，安腾瑞霖拥有行业领先的抗体药物开发、临床生产及商业化生产经验和平台优势，同时建立了符合国际GMP要求的质量体系。希望能在现有合作项目的基础上，持续加深双方合作，以更优质的创新药物尽早惠及病患。”
复宏汉霖高级副总裁兼首席运营官、安腾瑞霖董事长黄玮女士表示：“安腾瑞霖很高兴能为康抗生物提供CDMO服务，非常感谢康抗生物的信任。安腾瑞霖致力于以质量驱动的一体化生物制药开发生产平台，为客户新药研发生产赋能，在工艺开发、生产、注册申报等众多方面积累了丰富的经验。安腾瑞霖将持续秉持‘质量为本、诚信至上、高效协同、追求卓越’的理念，期待双方未来更深入的合作，助力推动康抗生物的项目申报上市进程，造福更多患者。”
■■■■
关于康抗生物
上海康抗生物由姜伟东博士于2021年在张江生物医药谷创办成立，是一家专注于提供创新药物的生物技术公司，以满足于临床未能满足的医疗需求。公司致力于开发免疫激动剂和多特异性抗体的创新型前药分子，以降低药物毒性、提高药物疗效。
公司创始人姜伟东博士曾与刘世高博士联合复星医药于2010年创办了上海复宏汉霖生物技术股份有限公司，并使其于2019年在香港证券交易所成功上市（2696.HK）。康抗生物正处在快速发展阶段，并将高效、创新、竞合、共赢视为公司的核心理念。
关于安腾瑞霖
安腾瑞霖（上海）生物科技有限公司是一家快速发展中的生物药CDMO（合同研发生产组织）公司，致力于以质量驱动的一体化生物制药开发生产平台，为客户新药研发生产赋能。公司服务范围涵盖从细胞株构建至商业化生产的端到端CDMO服务，包括单克隆抗体、融合蛋白、双特异性抗体、ADC（抗体药物偶联物）等的开发和生产。安腾瑞霖现已有两个研发和生产基地，其配套的质量管理体系符合中国国家药监局（NMPA）、欧洲药品管理局（EMA）及美国食品药品管理局（FDA）要求。
除业界领先的生产技术平台之外，安腾瑞霖建立了国际水平的生物医药研发、生产及运营管理团队，并拥有高素质的人才储备以及完善的团队架构。核心管理团队拥有来自领先跨国制药公司药物研发、临床、生产、CMC、质量与合规等方面平均超过15年的高级管理和行业经验。
KangaBio and Aton Biotech Enter into Strategic Collaboration Shanghai, China, Dec 13, 2022 — Aton Biotech, a fast-growing CDMO company which is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform, and Kangabio announced a strategic collaboration. Both parties expressed their aspiration for a long-term, comprehensive and strategic partnership to share resources and achieve joint development on the principle of equality and mutual benefits. During the cooperation, Aton Biotech will provide CDMO services for the innovative drugs of KangaBio, which includes cell line development, cell bank construction and verification, process development and optimization, analytical method development, process transfer and confirmation, clinical manufacturing, commercial scale manufacturing, stability study and IND & NDA filing support, etc.
“KangaBio is a biotech company focused on providing innovative medicine to address unmet medical needs. We are working on developing prodrugs of immune-stimulating agents and other multi-specific biologics to avoid toxicities for previously validated targets and to increase drug efficacy.” said Dr. Weidong Jiang, founder and CEO of Kangabio. “It is a great pleasure to reach this strategic cooperation with Aton Biotech. Aton Biotech has industry-leading antibody drug development, clinical production and commercial production experience and platform advantages, and has established a quality system that meets international GMP requirements. It is hoped that based on the existing projects, the cooperation between the two parties will continue to deepen, so as to benefit patients as soon as possible with better innovative drugs.”
“Aton Biotech is very pleased to provide CDMO services for KangaBio, and we are very grateful for the trust from KangaBio.” said Ms. Wei Huang, COO and SVP of Henlius and Chairman of Aton Biotech. “Aton Biotech is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform and has accumulated rich experience in many areas such as process development, manufacturing and regulatory. Aton Biotech will continue to uphold the concept of ‘quality, integrity, efficient, excellence’, and look forward to more in-depth cooperation between the two parties in the future to accelerate KangaBio’s molecule to market and benefit more patients.”
■■■■
About Kangabio
KangaBio is a biotech company focused on providing innovative medicine to address unmet medical needs. We are working on developing prodrugs of immune-stimulating agents and other multi-specific biologics to avoid toxicities for previously validated targets and to increase drug efficacy.
Dr. Jiang previously co-founded Shanghai Henlius Biotech in 2010, a public company listed on Hong Kong stock exchange with five successfully launched biologics in the Chinese market as well as one in the European market. KangaBio is growing rapidly and recruiting global talent, centering core values on efficiency, innovation, competition & collaboration, and win-win.
About Aton Biotech
Aton Biotech is a fast-growing CDMO company which is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform. Our service ranges from cell line development to clinical and end-to-end CDMO commercial manufacturing services, including development of mammalian expressed monoclonal antibodies, fusion proteins, bispecific antibodies, ADC, etc. Aton Biotech has two R&D &manufacturing sites in Shanghai. Both are equipped with the latest technology and fully compliant with the cGMP requirement of the NMPA, EMA and FDA.
In addition to the industry-leading manufacturing technology platforms, Aton Biotech has established an international level biopharmaceutical R & D, production, and operation management team, with high-quality talent reserve and perfect team structure. The core management team has more than 15 years of senior management and industry experience in drug R & D, clinical, production, CMC, quality, and compliance from leading multinational pharmaceutical companies.
业务咨询电话：021-33395966
业务咨询邮箱：BD@atonbio.com
官方网站：www.atonbio.com
